Latest Epidermal growth factor receptor Stories
African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.
Molecularly targeted therapies can reduce tumors rapidly.
Malignant gliomas are the most common subtype of primary brain tumor â€“ and one of the deadliest.
BETHESDA, Md., June 29 /PRNewswire-FirstCall/ -- Micromet, Inc.
RIDGEFIELD, Conn., May 20 /PRNewswire/ -- Boehringer Ingelheim will announce preliminary data in the areas of head and neck cancer and non-small cell lung cancer (NSCLC) for one of the company's investigational compounds, BIBW 2992.
Testing for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, especially when other testing methods are unavailable.
Levels of epidermal growth factor receptor (EGFR) may be elevated in the blood of women within 17 months prior to their breast cancer diagnosis.
- University of Toronto results of nimotuzumab linked to radionuclide - - Interaction of nimotuzumab with EGFRvIII, a mutant form of EGF receptor frequently expressed in brain tumors - MISSISSAUGA, ON, March 15 /PRNewswire-FirstCall/ - YM BioSciences Inc.
Peptides offer new approaches to interfere with EGFR and VEGFR pathways.
CAMBRIDGE, Mass., Feb. 22 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva(Â®) (erlotinib) in patients with non-small cell lung cancer (NSCLC).
- To fire mitraille at.